Dashboard
Manage Tickers

RMD


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stocks-edge-lower-as-fed-rate-decision-looms-treasury-yields-rise-as-odds-improve-for-smaller-cut-whats-driving-markets-wednesday
Stocks Edge Lower As Fed Rate Decision Loo...
09/18/2024 16:32:43

Wall Street is jittery hours before the highly anticipated Federal Open Market Committee (FOMC) meeting, with all major indices...

needham-reiterates-hold-on-resmed
Needham Reiterates Hold on ResMed
09/18/2024 10:06:47

Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Hold.

wolfe-research-downgrades-resmed-to-underperform-announces-180-price-target
Wolfe Research Downgrades ResMed to Underp...
09/18/2024 09:52:24

Wolfe Research analyst Mike Polark downgrades ResMed (NYSE:RMD) from Peer Perform to Underperform and announces $180 price t...

heres-how-much-you-would-have-made-owning-resmed-stock-in-the-last-15-years
Here's How Much You Would Have Made Owning...
09/09/2024 19:30:18

Core News & Articles
Apple Announces New Sleep Apnea Features O...
09/09/2024 17:18:16

a-glimpse-into-the-expert-outlook-on-resmed-through-6-analysts
A Glimpse Into The Expert Outlook On ResMe...
09/04/2024 14:01:00

needham-downgrades-resmed-to-hold-maintains-236-price-target
Needham Downgrades ResMed to Hold, Maintai...
09/04/2024 09:58:46

Needham analyst Mike Matson downgrades ResMed (NYSE:RMD) from Buy to Hold and maintains $236 price target.

how-is-the-market-feeling-about-resmed
How Is The Market Feeling About ResMed?
08/23/2024 19:45:19

1000-invested-in-resmed-10-years-ago-would-be-worth-this-much-today
$1000 Invested In ResMed 10 Years Ago Woul...
08/20/2024 19:30:13

if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-9500-today
If You Invested $1000 In This Stock 15 Yea...
08/07/2024 14:00:30

doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-others-in-your-portfolio
DoorDash And Exact Sciences Are Among Top ...
08/04/2024 14:32:50

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...

rbc-capital-maintains-sector-perform-on-resmed-raises-price-target-to-206
RBC Capital Maintains Sector Perform on Re...
08/02/2024 20:46:44

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $204 t...

keybanc-maintains-overweight-on-resmed-raises-price-target-to-251
Keybanc Maintains Overweight on ResMed, Ra...
08/02/2024 16:10:02

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $238 to $251.

resmed-earnings-reflect-increased-demand-for-sleep-devices-performance-indicates-positive-dynamics-opportunities
ResMed Earnings Reflect Increased Demand F...
08/02/2024 14:46:26

ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin...

resmed-shares-are-trading-lower-the-company-reported-q4-financial-results
ResMed shares are trading lower. The compa...
08/02/2024 11:37:06

needham-reiterates-buy-on-resmed-maintains-236-price-target
Needham Reiterates Buy on ResMed, Maintain...
08/02/2024 09:48:48

Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.

resmed-increases-quarterly-dividend-from-048-to-053
ResMed Increases Quarterly Dividend From $...
08/01/2024 20:25:32

resmed-q4-2024-adj-eps-208-beats-207-estimate-sales-1232b-beat-1217b-estimate
ResMed Q4 2024 Adj. EPS $2.08 Beats $2.07 ...
08/01/2024 20:07:50

ResMed (NYSE:RMD) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $2.07 by 0.48 per...

resmeds-options-frenzy-what-you-need-to-know
ResMed's Options Frenzy: What You Need to ...
07/30/2024 19:45:53

if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-16000-today
If You Invested $1000 In This Stock 20 Yea...
07/26/2024 16:00:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION